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BEST OF THE MONTH
A Roundup of Recently Published Articles Relevant to
Thoracic Oncology
Daniel Morgensztern, MD,* and Ramaswamy Govindan, MD†‡
Abstract: We selected six publications for the “best of the
month,” published recently in peer-reviewed journals, covering a
broad range of topics including second-hand smoking, intensive
care unit admissions for patients with lung cancer, role of aspirin
in preventing lung cancer, bleeding events in patients undergoing
treatment with bevacizumab and requiring full anticoagulation,
level of evidence used to support the National Comprehensive
Cancer Network guidelines, and the use of prophylactic cranial
irradiation in patient with locally advanced non-small cell
lung cancer.
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SECOND-HAND SMOKE
A Significant Cause of Lung Cancer Mortality
Although exposure to second-hand smoke (SHS) is
common in many countries and has been implicated in the
development of lung cancer, the magnitude of this problem
has not been very well described. Oberg et al.1 estimated the
burden of disease from SHS, measured as deaths or disabil-
ity-adjusted life years in 2004 using data from 192 countries,
and subdivided according to the global burden of disease.
Based on this study, the proportion of children, men, and
women exposed regularly to SHS were 40, 33, and 35%,
respectively. In adults, the most common cause of death from
SHS was ischemic heart disease (379,000 deaths), whereas
21,400 deaths were attributed to lung cancer. The relative risk
for the incidence of lung cancer was estimated at 1.21
(1.13–1.30) in exposures to SHS at home and 1.22 (1.13–
1.33) for exposures at work. Tobacco smoke is still a com-
mon indoor pollutant, and laws banning smoking in public
places could potentially decrease the risk of both acute
coronary events and lung cancer.
INTENSIVE CARE FOR PATIENTS WITH
NONRESECTABLE LUNG CANCER
Benefits Some
Intensive care unit (ICU) admissions for patients with
nonresectable lung cancer have been frequently questioned
because of the high mortality observed in this population.
However, patient outcomes have improved with advances in
both cancer-specific therapy and ICU care. Toffart et al.2
conducted a retrospective study to evaluate the 90-day and
1-year survival rates for lung cancer patients admitted to the
ICU in three tertiary-level hospitals in France between 2000
and 2007. Among the 105 eligible patients, the ICU and
overall inpatient mortalities were 31 and 48%, respectively.
Among the 71 (69%) patients discharged alive from the ICU,
the estimated 90-day and 1-year survivals were 54 and 18%,
respectively. The 90-day survival was similar in patients
requiring no ventilator assistance (40%) or noninvasive me-
chanical ventilation (47%), but it was significantly lower in
those requiring endotracheal mechanical ventilation (22%).
The main factors associated with increased 90-day mortality
were performance status Eastern Cooperative Oncology
Group 3 or 4 and metastases at admission. Although a small
number of patients may benefit from ICU care, the impor-
tance of discussing the end of life care issues with patients
newly diagnosed to have advanced lung cancer cannot be
overemphasized.
DAILY ASPIRIN AND THE RISK OF LUNG
CANCER
Benefit Restricted to Adenocarcinomas
Although daily aspirin has been shown to decrease the
risk of colorectal cancer, its effect on other malignancies has
not been established. Rothwell et al.3 evaluated data from
25,570 patients enrolled in 8 randomized trials comparing
daily aspirin with no aspirin. The use of aspirin decreased the
deaths for all cancers combined after a follow-up of at least 5
years. Regular use of aspirin was associated with a significant
decrease in the 20-year risk of death only in adenocarcinoma
of the lung (hazard ratio [HR] 0.55, p  0.04), whereas the
effect was not seen in squamous cell carcinomas of the lung
(HR 1.26, p  0.49) or small cell lung cancer (HR 0.85, p 
0.56). This preferential effect based on histology was also
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observed for other malignancies, with benefit from aspirin
also restricted to adenocarcinomas. Because adenocarcinoma
is the most common histology in lung cancer, aspirin may
have a significant chemopreventive effect. A phase III ran-
domized study is investigating the role of celecoxib in pa-
tients with metastatic non-small cell lung cancer (NSCLC)
who have cox-2 overexpression.4
CONCURRENT USE OF FULL DOSE
ANTICOAGULANTS AND BEVACIZUMAB IN
PATIENTS WITH ADVANCED CANCER
It Is Safe to Continue the Treatment Under
Full Anticoagulation
Thrombotic complications requiring anticoagulation
are common in patients with cancer and bevacizumab has
been associated with an increase risk of bleeding. In the phase
4 SAiL study, evaluating 2212 patients treated with first-line
bevacizumab-based therapy, grade3 thromboembolism and
bleeding were observed in 8 and 4% of the patients, respec-
tively.5 Similar rates of thromboembolism were observed in
the AVAiL trial, which compared gemcitabine, cisplatin,
and bevacizumab (GCB) with chemotherapy alone (GC) and
showed grade 3 venous thromboembolic events in 8 and
7% of the patients, respectively.6 Although the bleeding is
usually mild and self-limiting, severe episodes of hemoptysis,
central nervous system, and gastrointestinal bleeding have
been reported. Therefore, coagulation disorders or therapeutic
anticoagulation have been commonly used as exclusion cri-
teria for enrollment into bevacizumab trials. Nevertheless, a
major challenge arises when patients develop thrombotic
episodes while receiving bevacizumab. Leighl et al.7 evalu-
ated the safety of concurrent treatment with bevacizumab and
anticoagulation in two colorectal cancer studies and in the
AVAiL study. In the AVAiL study, among the 58 GCB
patients who started therapeutic anticoagulation for a throm-
botic event, 36 (62%) continued on study with chemotherapy
and bevacizumab, whereas 13 of 27 (48%) patients on the GC
group received concurrent therapy with chemotherapy and
anticoagulation. Grade 3 to 4 bleeding episodes occurred in
one patient treated with GC (8%) who developed central
nervous system bleeding and two patients (6%) treated with
gemcitabine, cisplatin, and bevacizumab, both developing
epistaxis. In the two colorectal cancer studies, grade 3 to 4
bleeding occurred in 0 to 7% of the anticoagulated patients
treated with chemotherapy alone and 3 to 4% of those treated
with chemotherapy plus bevacizumab. Therefore, it does not
seem that bevacizumab increases the risk of bleeding in
patients undergoing therapeutic anticoagulation.
LEVEL OF EVIDENCE FROM THE NATIONAL
COMPREHENSIVE CANCER NETWORK
GUIDELINES
Recommendations Based Mostly on Uniform
Consensus but with Lower Levels of Evidence
The National Comprehensive Cancer Network (NCCN)
provides the most frequently used oncology guidelines, ac-
cepted by the centers for Medicare and Medicaid services and
most private insurance companies. Poonacha and Go8 evalu-
ated the level of evidence for several malignancies from the
guidelines obtained from the website in July 2010. Level IIA
evidence (uniform NCCN consensus with lower level of
evidence) was the most commonly found, representing 83%
of recommendations, whereas 10% of the recommendations
were level IIB (lower level of evidence without NCCN
consensus but no major disagreement), 6% level I (high level
of evidence from randomized clinical trials and NCCN con-
sensus), and 1% level III (any level of evidence but with
major disagreement). Although 10% of the recommendations
for initial treatment and 6% of those for salvage therapy were
based on level I evidence, none of the workup or surveillance
recommendations were based on evidence higher than level
IIA. In lung cancer, the 238 recommendations were based
mostly on level IIA (80%), followed by IIB (12%), I (6%),
and III (2%). Level I evidence was the basis for 11% of the
recommendation on initial therapy for lung cancer and 6% on
salvage therapy. Although these guidelines are useful, these
data argue once again for thoughtful well-planned studies to
fill the knowledge gap.
PROPHYLACTIC CRANIAL IRRADIATION IN
PATIENTS WITH LOCALLY ADVANCED NSCLC
No Effect on Survival
Although prophylactic cranial irradiation (PCI) is
known to decrease the incidence of brain metastases (BM),
evidence of survival benefit has been shown only in
patients with small cell lung cancer.9 Nevertheless, the
increasing survival for patients with locally advanced
NSCLC and high risk of BM, frequently as the only site of
relapse, provided the rationale for the Radiation Therapy
Oncology Group 0214 trial,10 which randomized 356 pa-
tients with locally advanced NSCLC and no disease pro-
gression after initial therapy to undergo PCI with 30 Gy in
15 fractions or observation. Although PCI was associated
with a significant decrease in the rate of BM (7.7 versus
18%, p  0.004), there were no improvements in the
median disease-free survival rate (13.8 versus 12.3
months), median overall survival rate (25.8 versus 24.8
months), or 1-year overall survival rate (75.6 versus 76.9%).
In a separate analysis to evaluate the toxicity from PCI, the
treatment was associated with a significant decrease in
memory but not in the global cognitive function of quality-
of-life.11
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